Introduction
Enteral feeding of formulated food has a long history of use in inflammatory bowel disease (IBD) to correct or prevent malnutrition. More intriguing, and at the same time poorly understood, is the efficacy of enteral nutrition as primary therapy of intestinal inflammation in Crohn's disease, which will be the focus of this recent literature summary.
Treatment algorithms for Crohn's disease are changing rapidly. Increased and earlier use of immunomodulatory drugs and availability of biologic agents have reduced dependence on corticosteroids and made mucosal healing a realistic goal. It is timely to debate the place of enteral nutrition in this evolving therapeutic armamentarium, and to examine its mechanism of action in the framework of our current understanding of disease pathogenesis [1 ].
Enteral nutrition: treatment of active inflammation
This section will examine the current patterns of use as well as the evidence of efficacy.
Current patterns of use
Use and acceptance of enteral nutrition as therapy for active Crohn's disease differ substantially around the world. Enteral nutrition has had a special place in the management of paediatric Crohn's disease. Nevertheless, in a survey of practice patterns, 62% of Western European paediatric gastroenterologists reported frequent use of enteral nutrition, in contrast with only 4% of their North American colleagues [2] .
Centres in the United Kingdom continue to use enteral nutrition as first-line therapy among children with newly diagnosed Crohn's disease [3], but it was not even mentioned in a recent state-of-the-art North American review of paediatric therapy [4] . Such disparity is striking.
Further evidence of efficacy
Roughly 50-60% of patients treated with enteral nutrition in the clinical trial setting respond [5] . As with all therapies, response rates vary, depending on characteristics of the patient population; recent-onset disease may be more responsive [5, 6] . Although patients treated with corticosteroids more often achieve clinical remission [5] , it is well established that corticosteroids fail to induce mucosal healing [7] . Modern treatment paradigms call for interventions that achieve more than symptom control [4] . Endoscopic healing may be achieved with infliximab [anti-tumour necrosis factor alpha (TNF-a)] -the most studied of biologic agents [8] .
Small case series have previously described mucosal healing and down-regulation of pro-inflammatory cytokines with enteral nutrition [9] . During the past year, several paediatric groups have performed follow-up endoscopic assessments following exclusive enteral nutrition [10 ,11] . A retrospective comparative analysis reported greater endoscopic and histologic improvement in newly diagnosed paediatric patients treated with enteral nutrition, even though clinical response rate with corticosteroid therapy was comparable [10 ] . This observational study also suggested a longer duration of clinical remission following attainment of mucosal healing [10 ] . In a prospective study of 65 children, Afzal et al. [11] reported improvements in endoscopic and histologic mucosal assessments of patients with ileal or ileo-colonic disease after treatment. The mucosal effects of enteral nutrition should continue to be examined, ideally in a prospective, randomized study, in which those assessing the mucosal response are blinded to the treatment group.
A therapy is more likely to be accepted if the mechanism by which it ameliorates intestinal inflammation is understood. The mode of action of enteral nutrition remains conjectural.
Enteral nutrition: mechanisms of efficacy
Hypotheses have included overall nutritional repletion, provision of important specific micronutrients to the diseased intestine, elimination of dietary antigen uptake, diminution of intestinal synthesis of inflammatory mediators via reduction in dietary fat, and alteration of intestinal microbial flora [1 ] . As reviewed by Sanderson [12 ] , constituents of the intestinal lumen can alter the expression of molecules in intestinal epithelial cells, which, in turn, direct the mucosal immune system. Most recent research has focused on the role of lipids in modulating intestinal inflammation, with some studies attempting to explore the importance of changes in the enteric flora observed with enteral nutrition.
The importance of the fat content of formulated food to efficacy in Crohn's disease has been succinctly reviewed by Gorard [13] . Dietary lipids can modulate inflammation by a variety of mechanisms which influence cellular production of cytokines and eicosanoids. Omega-6 polyunsaturated fatty acids (n-6 PUFAs) are precursors of arachidonic acid -an important substrate for the production of pro-inflammatory eicosanoids. In contrast, n-3 PUFAs, which are abundant in fish oils, inhibit arachidonic acid production and inhibit protein kinase C activity needed for TNF release from macrophages. Excess n-6 PUFAs would be expected to attenuate the effect of enteral nutrition in treating Crohn's disease, whereas a relative increase in n-3 PUFAs might be beneficial.
Whiting et al. [14] examined the hypothesis that a diet enriched in n-3 PUFAs would prevent or ameliorate disease in a well characterized severe combined immunedeficiency (SCID) mouse model of chronic colitis that resembles Crohn's disease. Animals were fed either a standard diet or a diet enriched in n-3 PUFAs both before and following induction of colitis by injection of CD4 þ CD45RB high T cells. In comparison with animals fed a standard diet, the n-3-fed animals had similar immune cell infiltration, but significantly reduced disease scores, reduced neutrophil infiltration and lower mucosal levels of pro-inflammatory cytokines (TNF-a, IL-1b and IL-12). Expression of epithelial tight junction protein ZO-1 -a marker of intestinal permeability -was also better preserved, suggesting improved epithelial barrier function. The authors interpret their findings as demonstrating that n-3 PUFAs reduce inflammation by reducing myeloid cell infiltration and activation, which, in turn, means lower levels of cytokines and less damage to the barrier. Although not preventing the immune cellmediated colitis in this model, n-3 PUFAs contribute to breaking the chronic cycle of immune cell activation/ reduced barrier function.
Clinical trials [13, 15, 16] employing formulae with disparate fat contents have yielded conflicting results. Response rates among patients treated by Bamba and colleagues [15] decreased as the amount of soybean oil (predominantly linoleic acid -an n-6 PUFA) in the elemental formula was increased. A well designed multi-centre European study [16] , however, was stopped early because of a low remission rate in one of the enterally fed groups. Of compliant patients treated with a diet high in linoleate (n-6 PUFA) and low in oleate (monounsaturated fatty acids), 67% achieved remission compared with only 27% of those compliant with a formula low in linoleate and high in oleate. These two clinical trials and earlier ones suggest that the magnitude of response to enteral nutrition is influenced by lipid composition, but the relative importance of specific fatty acids seems variable. More importantly, while the amount and type of fat may modulate inflammatory pathways, the therapeutic success achieved with a variety of both polymeric (usually high-fat) and elemental (usually low-fat) formulae suggests that efficacy does not depend solely on fat content.
Effects of enteral nutrition on the gut microbial flora deserve further exploration, in light of the now well established role of microbes in disease pathogenesis [17] . Molecular approaches to the identification of bacterial species are now feasible. A recent small study [18 ] among children with Crohn's disease demonstrated that the enteric microflora is modified during and after a course of exclusive enteral nutrition. Alterations in bacterial populations may alter interactions with the intestinal epithelium, thereby leading to modulation of inflammation. It is as yet unclear, however, whether the observed changes in the intestinal flora occur as a response to the administration of enteral nutrition, or as a consequence of decreased inflammation. Comparison with patterns of microflora following other therapies might help to answer this question.
The general consensus is that the protein source of formulated food (intact protein compared with protein hydrolysate compared with amino acids) does not influence the efficacy of enteral nutrition in treating active Crohn's disease [1 ,5] . Given the influence (albeit small) of fat content on efficacy, this reviewer recommends a conventional elemental liquid diet (because of the low fat content) if naso-gastric tube feeding is to be employed. If a patient wishes to drink formula, palatability is important and a polymeric feed is required. Other aspects of therapeutic regimens have been addressed in recent studies.
Enteral nutrition: defining therapeutic regimens
First, we will look at patient selection and exclusive compared with supplementary enteral nutrition.
Patient selection
Anecdotally active Crohn's disease confined to the colon has been considered relatively refractory to enteral nutrition, but randomized controlled trials have seldom reported site-specific response rates. In the cohort study of Afzal and colleagues [11] , the subgroup of patients without ileal disease demonstrated less of a clinical response and failed to show significant endoscopic improvement. The phenotypic expression of Crohn's disease varies, it is hypothesized, depending on the influence of susceptibility and modifier genes as well as exogenous factors [19, 20] . Location of macroscopic inflammation is one phenotypic characteristic which tends to remain stable over time [21] . Given that etiopathogenic mechanisms differ depending on localization of Crohn's disease, corresponding variation in responsiveness to treatment is not surprising. It is intriguing that altered innate immunity has been most convincingly demonstrated in Crohn's disease involving the ileum [20] . It would be interesting to study whether Crohn's disease-associated polymorphisms in the NOD2/CARD15 gene predict responsiveness to enteral nutrition in patients with small intestinal disease.
Exclusive compared with supplementary enteral nutrition
Exclusive enteral nutrition (EEN) was compared with partial enteral nutrition (PEN) and an unrestricted diet in a recent randomized controlled paediatric trial [22 ] . EEN provided 100% of calculated energy requirements, and PEN only 50%. Among 50 children included in the study, remission rate was significantly lower (15%) with PEN than with EEN (42%) (P ¼ 0.035). Moreover, only EEN led to a reduction in markers of inflammation. Whilst supplementary enteral nutrition may benefit nutritional status and sense of 'well-being', exclusive feeding of formulated food appears to be required for anti-inflammatory effects. One wonders, however, whether regular food would still have compromised efficacy, if formulated food had provided a greater percentage of energy requirements. Avoidance of regular food is a major deterrent to acceptance of enteral nutrition as a therapy of active inflammation.
The tendency of Crohn's disease to relapse following cessation of therapy -a problem common to all medical regimens -is often cited as another reason for lack of use of enteral nutrition as primary therapy. Short-term relapse rates following use of enteral nutrition for Crohn's disease of long duration in adults have been documented [23] . What has never been addressed, however, is whether use of enteral nutrition at diagnosis alters the subsequent clinical course. Demonstration of longterm benefit would justify the inconveniences of enteral nutrition and demand reconsideration of North American treatment paradigms, which rely solely on drugs.
Enteral nutrition: long-term outcomes
In order to assess the long-term outcomes, we need to examine the clinical course of disease activity and growth.
The clinical course of disease activity
Paediatric gastroenterologists in Bristol, England, undertook to describe long-term outcomes among children whose first treatment had been enteral nutrition [4] . Among 79 patients newly diagnosed over a 7-year period, 44 (55%) chose to be treated with a 6-week course of enteral nutrition (73% via naso-gastric tube) rather than with oral corticosteroids [4] . Cumulative relapse rates were not reported, but median time to relapse was 54.4 weeks. These uncontrolled data suggest that some children experience a long asymptomatic interval after first treatment with enteral nutrition. However, data concerning the time to relapse in the steroid-treated group were not provided, so the spectrum of long-term outcomes following nutritional compared with pharmacologic treatment cannot be compared.
Growth
Enteral nutrition has been an important therapeutic option for paediatric patients by virtue of its ability to both provide nutrients and down-regulate intestinal inflammation, thereby facilitating normal growth. Proinflammatory cytokines and under-nutrition are the two major factors contributing to impairment of linear growth in children with Crohn's disease [24] . Some growth-impaired children with Crohn's disease remain stunted despite provision of adequate calories and good weight gain, presumably because their chronic intestinal inflammation has not been treated by enteral nutrition. Bannerjee et al. [25] recently provided data showing that EEN was associated with a rapid decrease in elevated IL-6 -a cytokine associated with decreased linear growth rate. C-reactive protein and an increase in IGF-1 were noted by 1 week, whereas measures of nutritional status did not improve until later. It is increasingly recognized that cytokines impair linear growth through a multiplicity of pathways; in facilitating growth, the emphasis must be placed on achieving and maintaining mucosal healing [24, 26, 27] . Use of enteral nutrition and immunomodulatory therapies is not mutually exclusive. Newly diagnosed children with Crohn's disease may be treated with enteral nutrition rather than a course of corticosteroids, at the same time as immunomodulatory drugs are initiated to subsequently maintain remission [28] . Among a subgroup of children with extensive Crohn's disease, chronically active despite azathioprine or methotrexate therapy, control of intestinal inflammation and significant enhancement of weight gain and linear growth have been achieved with sustained anti-TNFa therapy [29] .
Conclusions
Use of enteral nutrition as primary therapy of Crohn's disease, although uncommon in North America, is standard care among newly diagnosed children in many centres elsewhere. The necessary regimens and Crohn's disease phenotypic features influencing responsiveness have now been well defined. The inconveniences of exclusive feeding of formulated food and the lack of demonstrated long-term benefits from short-term use combine to explain the frequent omission of enteral nutrition from therapeutic algorithms, despite evidence of efficacy in down-regulating mucosal inflammation.
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